Upregulated EGFR/MEK1/MAPK1/2 signaling also occurs in 4-hydroxytamoxifen-resistant MCF-7 breast cancer cells and blocks BimEL-dependent apoptosis (55). This evidence concerns the gene BCL2L11 and breast carcinoma.